Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Investor Presentation (July 2024)
14 slides from Laboratorio Reig Jofre's investor presentation, July 2024
Slide 1: Reig Jofre CMO Services
REIG JOFRE CMO Services ADDITIONAL INFO reigjofre.es
Slide 2: Declaration
DECLARATION This presentation does not contain confidential material and may include publicly available market information that has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. The information contained in this presenta
Slide 3: Reig Jofre Today
REIG JOFRE TODAY Global benchmark in essential With an extensive And with solid financial solutions for the health of everyone international track record results to back us up 95 years of history Revenues 2023 by country €316 M sales in 2023, +17% Asia 8% Diversified product Rest of UE Oceania 1% po
Slide 4: Reig Jofre - The Story
REIG JOFRE - THE STORY • RJ Poland • EU agreement to reserve • New Injectables plant in vaccine production capacity Food Barcelona supplements Osteoarticular • Sweden plant expansion 2023 • Merger with 2021 Natraceutical • Acquisition of Prescription and BioIbérica OTC Derma & • IPO 2022 Respiratory
Slide 5: International presence and sales 2023
INTERNATIONAL Rest of Rest of TOTAL PRESENCE Sed ut perspiciatis SALES 2023 Sed ut perspiciatis PERFORMANCE SPAIN EUROPE WORLD +70 COUNTRIES €316 M 45% €141.1 M 43% €137.7 M 12% €37.3 M → All geographic areas +19% +8% +47% DIRECT SALES increased sales over 2022 → The other European markets 8 COUNTRI
Slide 6: Reig Jofre Sales 2023
REIG JOFRE SALES 2023 PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC / Energy / Stress and sleep / Injectables / Lyophilised Dermatology Weight control / Beauty 44 % € 138.7 M +11% 33% €105.1 M +31% 23% €72.3 M +10% The global demand for antibio
Slide 7: Pharmaceutical Technologies in 2023
PHARMACEUTICAL TECHNOLOGIES IN 2023 22% Development and 78% Product Developed by PHARMACEUTICAL TECHNOLOGIES 44% Manufacturing REIG JOFRE MANUFACTURING IN-HOUSE COMMERCIAL LICENSING DISTRIBUTION Antibiotics € 139 M CDMO NETWORK AGREEMENTS Injectables / Lyophilised +11% €31 M €36 M €72 M +29 % +3% +1
Slide 8: Manufacturing & Development Facilities Barcelona, Toledo & Malmö
Manufacturing & Development Barcelona, Toledo & Malmö Facilities BARCELONA (SPAIN) TOLEDO (SPAIN) MALMÖ (SWEDEN) State-of-the-art facilities for injectable Specialized facilities in betalactam antibiotics development & Faciliies specialized in topical dermatological products development & manufactur
Slide 9: New Injectable Plant ZE3 (Barcelona)
NEW INJECTABLE PLANT ZE3 (BARCELONA) (liquid & freeze-dried vials) STATE-OF-THE-ART INJECTABLE MANUFACTURING NEW PEOPLE ANNUAL PLANT / HIGH CAPACITY & TECHNOLOGY INVESTMENTS CONTRACTED CAPACITY +100 +30M 2018 2020 2021 Project launch Adaptation for vaccines manuf. AEMPS Authorization 40M€ VIALS 15 M
Slide 10: New Injectable Plant / Line IV (Toledo)
NEW INJECTABLE PLANT / LINE IV (TOLEDO) (penicillin powder aseptic filled vials) STATE-OF-THE-ART INJECTABLE MANUFACTURING NEW PEOPLE ANNUAL PLANT / HIGH CAPACITY & TECHNOLOGY INVESTMENTS CONTRACTED CAPACITY 10M€ +30 +15M 2016 2017 2018 Project launch Finishing new building & AEMPS installation of n
Slide 11: International Milestone
2013 We began specific development for the Japanese market INTERNATIONAL 2016 We initiated the commercialization of injectable anesthetics in Japan MILESTONE 2019 We reached 5 million treatments, and by 2023, we reached 15 million Surpassing 15 Million treatments - OctoberBarcelona, 27, 2023 Spain S
Slide 12: EU FAB Project
EU FAB PROJECT to ensure vaccine manufacturing and supply capacity in Europe in the event of a health emergency European Commission EVER-WARM Agreement signed on July 1, 2023 (4 years) with the European <30% Health Emergency Preparedness and Commission: Response Authority – HERA CAPACITY REIG JOFRE,
Slide 13: Reig Jofre - Sustainability
REIG JOFRE - Sustainability ENVIRONMENT SOCIAL GOVERNANCE CO2 emissions Sustainability Plan Circular economy People Community European Green Taxonomy Use of resources Risk plan CO2 emissions Water consumption Culture & Engagement Sustainability 2,584 –10% 59% +7% Startof Sustainability Strategy Taxo
Slide 14: Contact details
Av. de les Flors 08970 Sant Joan Despí BARCELONA, SPAIN T. +34 93 480 67 10 www.reigjofre.com Relación con Inversores investors@reigjofre.com